£6.0M
The funding will support Phase I clinical trials for the company lead antimicrobial candidate.
CT
Centauri Therapeutics
Centauri Therapeutics develops novel immunotherapies to target multidrug-resistant Gram-negative bacteria.
United Kingdom—Founded 2019
£7.0MTotal raised
A British biotechnology firm developing immunotherapies to combat drug-resistant bacterial infections using its proprietary Alphamer platform.
Filed accounts
Cash at bank
Members only
Net current assets
Members only
Total assets less current liabilities
Members only
Net assets
Members only
Shareholders' funds
Members only
Fixed assets
Members only
Cash, assets and headcount from Centauri Therapeutics's latest Companies House filing — with year-on-year movement, free with a Winfred account.
Categories
Team
Stuart Lawson
Founder
Stuart serves as CEO at Animatrix Founders and holds chief financial officer roles across multiple organisations, including TypeDB, ReadingWise, and Your Body Data. He also acts as a director at Centauri Therapeutics, having previously founded the company.
LinkedIn
Investors
- £6.0M
- £1.0MPPACELead
Funding history
£1.0M
Centauri Therapeutics has secured £1m from PACE to develop its Alphamer technology targeting drug-resistant bacterial strains.